Cambridge, Mass., USA - June 4, 2010, Cambridge, Mass., USA - Curis, a drug development company, announced the appointment of Marc Rubin to its board of directors.
Article continues below
Dr. Rubin has served as Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. since May 2009. He held the position of President and Chief Executive Officer of Titan Pharmaceuticals from October 2007 until December 2008.
From June 2006 until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma.
Beginning in October 2003 and until the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG with responsibility for global development and for three global business units, including the oncology business unit, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG.
From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine.
Prior to his pharmaceutical industry career, Dr. Rubin completed subspecialty training and board certification in both medical oncology and infectious diseases at the National Cancer Institute within the National Institutes of Health (1983-1986).
Dr. Rubin also served as an Investigator and on the Senior Staff of the infectious diseases section at the National Cancer Institute from 1986 until 1989. Dr. Rubin holds an M.D. from Cornell University Medical College.
In addition to his role of Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Dr. Rubin currently serves on the board of directors of Surface Logix, a biotechnology company, and the Rogosin Institute, a medical treatment and research institution. ■